Original Article

EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis

Shuai Wang, Zhou Wang

Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, P. R. China

Received May 30, 2014; Accepted June 14; Epub August 15, 2014; Published August 30, 2014

Abstract: Many studies have reported the EGFR mutations in Chinese non small cell lung cancer (NSCLC) patients and their relationship with clinicopathological characteristics. But the frequency and type of EGFR mutations are varied. The relationship between EGFR mutations and clinicopathological characteristics remains unclear. We systematically reviewed studies of EGFR mutations in mainland Chinese NSCLC patients. Standard statistical methods for meta-analysis were applied. A total of 5,442 patients from 21 studies were included in the meta-analysis. The overall EGFR mutation rate was 37.5\% (2,039/5,442). Among those 1,935 patients with detailed data about EGFR mutation types, the most prevalent mutation type was L858R, which accounted for 38.3\% of all EGFR mutations. EGFR-TKIs sensitive mutations occupied 88.5\% of all EGFR mutations. While the acquired EGFR-TKIs resistant mutations (T790 M) could occur naturally at the frequency of 1.5\% without exposure of EGFR-TKIs. Male patients had a lower mutation rate than female patients (32.6\% versus 53.0\%, OR=0.40, 95\% CI: 0.34 - 0.48, P < 0.001). The EGFR mutation rate for smokers was 19.2\%, lower than that for non-smokers (47.9\%) (OR = 0.40, 95\% CI: 0.34 - 0.48, P < 0.001). Patients with adenocarcinoma had a higher mutation rate than those with non-adenocarcinoma (50.2\% versus 17.0\%, OR = 4.84, 95\% CI: 4.07 - 5.75, P < 0.001). EGFR mutation rate did not differ significantly between stage I and stage II/III/IV patients (35.8\% versus 32.2\%, OR = 1.08, 95\% CI: 0.84 - 1.43, P = 0.580). Our results show that EGFR mutation rate is high in mainland Chinese NSCLC patients. EGFR-TKIs sensitive mutations are main types of mutations. EGFR mutations are significantly associated with gender, smoking history, histology type, but not stage.

Keywords: Non-small cell lung cancer, EGFR, mainland China, targeted therapy, clinicopathological features, mutation analysis

Introduction

Lung cancer is a leading cause of mortality in both the developing and developed worlds, with ~1.18 million deaths reported every year [1]. Non-small cell lung cancer (NSCLC) accounts for ~85\% of all lung cancers and about 70\% of patients with NSCLC are primarily diagnosed at late stage [1], which results in poor prognosis.

It was discovered that epidermal growth factor receptor (EGFR) mutations are related to the pathogenesis of NSCLC. EGFR, a member of receptor tyrosine kinases superfamily, can bind to extracellular ligands, dimerize with each other and auto-phosphorylate [2]. Then, EGFR acts as a key regulatory molecule in cellular signaling pathways, promoting tumor cell proliferation, invasion and metastasis [3]. In NSCLC, EGFR is over-expressed by 40 to 80\% and the expression levels are correlated with the EGFR tyrosine kinase domain mutations [4]. Recently, EGFR tyrosine kinase inhibitors (TKIs) have been developed for the treatment of advanced NSCLC [5]. Unfortunately, only one part of lung cancer patients is sensible to EGFR-TKIs. In 2004, Lynch et al. reported that EGFR mutations are related to the sensitivity of NSCLC to gefitinib [6], which brings NSCLC into the realm of personalized medicine. Subsequently, many publications have revealed that somatic mutations of the EGFR gene constitutively enhanced EGFR tyrosine kinase activity [7, 8].
Currently, EGFR-TKIs are recommended to be the second- or third-line agents for advanced NSCLC. Even EGFR-TKIs are recommended as the first-line agents for patients with EGFR mutations [9]. However, phase III trials with EGFR-TKIs in patients with NSCLC had demonstrated that gefitinib did not show any survival gain over placebo. Further analysis found that patients who had never smoked and were of Asian origin seemed to have a significant survival benefit from gefitinib [10]. One possible reason is that this study was conducted in unselected patients with NSCLC. Thus, detection of the EGFR mutation status in patients with NSCLC is necessary for an appropriate use of EGFR-TKIs.

About 10% of European patients with NSCLC harbor EGFR mutations and 31% in Asian [11-13]. However, several studies reported that the frequency of EGFR mutations in mainland China is varied ranged from 19.2% to 55.8% [14-16]. The mutations of EGFR in NSCLC had been founded to be associated with many demographic and clinicopathological factors, including race, gender, smoking status and tumor histology [14]. Shigematsu et al. reported that patients associated with female gender, never smokers, Asian ethnicity and adenocarcinoma histology are sensible to EGFR-TKIs [17]. But results of some publications from Mainland China are inconsistent with those findings [18-20]. So, the relationship between EGFR mutations and clinicopathological features is unclear in patients with NSCLC from mainland China. Given the current knowledge in the field, the EGFR mutation status of NSCLC patients in mainland China have to be considered in the use of EGFR-TKIs. Furthermore, most previous studies on EGFR mutations primarily focused on adenocarcinoma (ADC), few studies have evaluated the EGFR mutations in non-adenocarcinoma NSCLC (NADC) in large scale. Comprehensive review of EGFR mutations is essential for individualized molecular targeted therapy for NSCLC. We thus conducted this meta-analysis of updated data from mainland China to clarify EGFR mutation status and correlations between EGFR mutations and clinicopathologic characteristics in NSCLC patients.

Materials and methods

Search strategy and selection criteria

We searched the PubMed, EMBASE, Cochrane Library as well as Chinese biomedical literature databases to identify all the articles with the combination of the following keywords: “epidermal growth factor receptor mutation” or “EGFR mutation”, “lung” or “pulmonary”, “non-small cell lung cancer” or “NSCLC” or “adenocarcinoma” or “squamous cell carcinoma” and “China” or “Chinese”. Meeting abstracts from the American society of Clinical Oncology (ASCO) and World Congress of Lung Cancer (WCLC) were also hand searched. Reference lists of original articles and review articles were also examined. All articles were identified by use of the related-articles function in PubMed. The published languages were English or Chinese and the literature search was conducted up to January 5, 2014.

Results from the initial search that match the criteria below were eligible. (a) The studies must determine EGFR mutation status of primary NSCL tissues at least including exons 18-21; (b) Individuals with NSCLC must be histologically confirmed; (c) Any patients did not receive chemotherapy or radiotherapy or treatment with EGFR-TKIs before detection of EGFR mutations; (c) The demographic characteristics of pathology, gender, age, smoking history and stage were measured; (d) Studies have no restrictions on the methods of obtaining the tissue specimens and EGFR mutation detection. The studies were excluded if (a) patients that were not from mainland China; (b) patients with small cell lung cancer or other malignancies or benign lung tumors; (c) number of patients with NSCLC less than 40. If the same patient population was used in more than one study, only the complete study would be included.

Data extraction

Two independent authors extracted all data from the identified studies using standardized data compilation forms and disagreements were resolved by discussion to validate the accuracy of extraction. The following information was extracted from all included studies: the first author, year of publication, number of included patients, age, EGFR mutation status, gender, smoking history, histology types, tumor-node- metastasis (TNM) stage, tissue sample and detection method of each study. The numbers of cases with EGFR mutations from each study were collected to evaluate mutation frequency among NSCLC, meanwhile, the mutation types were also collected from some studies who displayed the data.
Patients who had smoked < 100 cigarettes in their lifetime were identified as ‘non-smokers’. Patients who had smoked > 100 cigarettes in their lifetime were identified as ‘smokers’. Smoking status was based on records of original studies. The diagnosis of pulmonary adenocarcinoma (ADC) was based on the histopathological findings, and pulmonary non-adenocarcinoma NSCLC (NADC) included squamous carcinoma, adenosquamous carcinoma, large cell carcinoma, sarcomatoid carcinoma, and mucoepidermoid carcinoma. TNM staging was determined by the records of original studies.

Statistical analysis

The relationship between EGFR mutations and demographic and clinicopathological characteristics was analyzed by Meta-analysis. The $X^2$-based Q test and I$^2$ statistic were performed to quantify heterogeneity. I$^2$ statistic with values > 50% and $X^2$ test with $P < 0.05$ indicate strong heterogeneity between the studies [21].

Results

Literature search and study characteristics

Our search in electronic database and meeting abstracts retrieved 463 references. The selection steps were summarized in the flow diagram shown in Figure 1. Twenty one studies were finally enrolled, including 8 studies of full publications in English [14, 16, 23-28], 9 studies of full publications in Chinese [29-37] and 4 studies of meeting abstracts [15, 38-40]. Totally, 5,442 NSCLC patients with individual patient data were meta-analyzed for EGFR mutations in our study. Those patients came from twenty medical centers in Guangzhou, Beijing, Shanghai, Changchun, Tianjin, Nanjing, Urumqi, Xi’an, Xiamen and Chengdu.

The Mantel-Haenszel method and the DerSimonian and Laird method were used to determine the choice of fixed-effects model or the random-effects model. When $P$ value was $\geq 0.05$, the fixed-effects model was more appropriate. Otherwise, the random-effects model was used to provide wider confidence interval (CI). The pooled odds ratio (OR) and 95% CI were calculated. The meta-analysis results were displayed as forest plots. Sensitivity analysis was performed by excluding each study at a time individually and recalculating the ORs and CIs. Potential publication bias was analyzed by Begg’s funnel plots and Egger’s linear regression test [22]. $P < 0.05$ by t test was considered statistically significant publication bias. This meta-analysis was performed by using the software Stata 11.0 (Stata Corporation, College Station, TX). All the $P$ values were two-sided. Differences were considered statistically significant at $P < 0.05$. 

Figure 1. Study flow chart showing process for selecting eligible publications.
Table 1. Characteristics of studies included in the meta-analysis

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Cases</th>
<th>Age</th>
<th>Gender</th>
<th>Smoking</th>
<th>Histology</th>
<th>TNM stage</th>
<th>Detection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Qin B, 2005 [23]</td>
<td>41</td>
<td>NA</td>
<td>10</td>
<td>31</td>
<td>20</td>
<td>17</td>
<td>24</td>
</tr>
<tr>
<td>Li Y, 2013 [26]</td>
<td>208</td>
<td>NA</td>
<td>51</td>
<td>157</td>
<td>147</td>
<td>61</td>
<td>130</td>
</tr>
<tr>
<td>Jing C, 2013 [27]</td>
<td>120</td>
<td>62</td>
<td>48</td>
<td>72</td>
<td>69</td>
<td>51</td>
<td>NA</td>
</tr>
<tr>
<td>Liu Y, 2013 [28]</td>
<td>251</td>
<td>NA</td>
<td>140</td>
<td>111</td>
<td>138</td>
<td>113</td>
<td>NA</td>
</tr>
<tr>
<td>Zhang Y, 2013 [29]</td>
<td>99</td>
<td>NA</td>
<td>33</td>
<td>66</td>
<td>68</td>
<td>31</td>
<td>43</td>
</tr>
<tr>
<td>Zhang J, 2008 [29]</td>
<td>82</td>
<td>61</td>
<td>42</td>
<td>40</td>
<td>48</td>
<td>34</td>
<td>40</td>
</tr>
<tr>
<td>Yin X, 2010 [31]</td>
<td>107</td>
<td>61</td>
<td>30</td>
<td>77</td>
<td>82</td>
<td>25</td>
<td>60</td>
</tr>
<tr>
<td>Feng Q, 2011 [32]</td>
<td>309</td>
<td>59.7</td>
<td>105</td>
<td>204</td>
<td>184</td>
<td>125</td>
<td>132</td>
</tr>
<tr>
<td>Sun M, 2011 [33]</td>
<td>443</td>
<td>57</td>
<td>189</td>
<td>254</td>
<td>243</td>
<td>200</td>
<td>NA</td>
</tr>
<tr>
<td>Wang L, 2011 [35]</td>
<td>184</td>
<td>58.5</td>
<td>69</td>
<td>115</td>
<td>106</td>
<td>78</td>
<td>79</td>
</tr>
<tr>
<td>Gao J, 2012 [36]</td>
<td>120</td>
<td>65</td>
<td>44</td>
<td>76</td>
<td>77</td>
<td>43</td>
<td>60</td>
</tr>
<tr>
<td>Sun L, 2013 [37]</td>
<td>301</td>
<td>59</td>
<td>99</td>
<td>202</td>
<td>174</td>
<td>127</td>
<td>173</td>
</tr>
<tr>
<td>Zhang X, 2005 [38]</td>
<td>76</td>
<td>62.5</td>
<td>31</td>
<td>45</td>
<td>41</td>
<td>35</td>
<td>NA</td>
</tr>
<tr>
<td>Wu Y, 2005 [39]</td>
<td>142</td>
<td>60</td>
<td>42</td>
<td>100</td>
<td>98</td>
<td>44</td>
<td>84</td>
</tr>
<tr>
<td>Zhang L, 2005 [40]</td>
<td>52</td>
<td>58</td>
<td>10</td>
<td>42</td>
<td>39</td>
<td>13</td>
<td>33</td>
</tr>
<tr>
<td>Zhou C, 2005 [41]</td>
<td>81</td>
<td>62</td>
<td>21</td>
<td>60</td>
<td>52</td>
<td>29</td>
<td>41</td>
</tr>
</tbody>
</table>

Abbreviations: Age: median age; M: mutant type EGFR; W: wild type EGFR; M: male; F: female; Y: smoker; N: non-smoker; ADC: adenocarcinoma; NADC: non-adenocarcinoma NSCLC; NA: not available; FFPE: formalin-fixed, paraffin-embedded tissues; SFILN: snap-frozen tissues in liquid nitrogen; SE: sequencing; HRM: high resolution melting analysis; ARMS: amplification mutation refractory system; BPSP: bi-loop probe and specific primer quantitative PCR.

Generally, 5,442 enrolled patients included more males than females: the male: female ratio was 1.6:1. Median age was reported in 17 studies, which reported a median age of 55.3-65 years. There were more smokers than non-smokers: the smoker: non-smoker ratio was 1.1:1. There were also more ADC patients than NADC patients: ADC patients: NADC patient’s ratio was 2.0:1. The ratio of patients in stage I to patients in stage II/III/IV was 0.5:1. Specimens were obtained from formalin-fixed, paraffin-embedded tissues (FFPE) in 19 studies. Only 1 study used snap-frozen tissues in liquid nitrogen (SFILN) analysis and 1 study of fresh tumor tissues detection. As illustrated in Table 1, the most common detection method was sequencing: 14 studies carried out sequencing alone or with other methods. Seven studies used other detection methods: 5 studies of amplification mutation refractory system (ARMS) analysis, 1 study of high resolution melting (HRM) analysis and 1 study of bi-loop probe and specific primer quantitative PCR (BPSP-qPCR). Articles reporting data on EGFR mutations were examined to assess their scope. Screening of EGFR mutations was variable, however, all reports included exons 18-21, where more than 96% of mutations have been reported based on EGFR Mutations Database (http://somaticmutations-egfr.org/NSCLC.html).

EGFR mutation patterns

Mutations in the EGFR gene exons 18-21 were detected in 2,039 of 5,442 NSCLC patients. The overall EGFR mutation rate was 37.5%. The data from meeting abstracts lacked information about mutation types. Types of EGFR mutation were available from 1,935 patients. As shown in Figure 2A, the distribution of EGFR mutations was that 66 were in exon 18 (3.4%), 906 were in exon 19 (46.8%), 71 were in exon 20 (3.7%) and 812 were in exon 21 (42.0%). There were 80 patients (2.9%) that had double or multiple mutations. The most common type of double or multiple mutations was mutations in exons 19 and 21 (25.0%, 20/80). Details of the EGFR mutations are comprehensively reviewed from eligible studies. There were 73
EGFR mutations in mainland Chinese NSCLC patients

kinds of EGFR mutations in exons 18-21. Figure 2B showed the most common 27 kinds of mutations. In mainland Chinese patients with NSCLC, the most prevalent mutation types were L858R in exon 21 and del(746-750) in exon 19, which accounted for 38.3% (741/1935) and 37.0% (716/1935) of all EGFR mutations, respectively. In exon 18, G719C was dominant mutation type (43.9%, 29/66). Del(746-A750), del(747-749)ins(S), del(747-751), del(746-752), del(747-749)ins(P) and del(747-753) were the six major in-frame deletions in exon 19, which occupied 90.4% (819/906) of exon 19 mutations. T790M and insertion mutations accounted for 71.8% of all exon 20 mutations. The four major mutations (87.5%, 792/812) in exon 21 were L858R, L858M, L861R and L861Q. The rate of EGFR-TKI sensitive mutations was 88.5% (1713/1935), including exon 19 deletion, L858R, L861Q, G719X (G719C, G719S, G719A). The rate of EGFR-TKI resistant mutations was 2.6% (76/1935), including exon 20 insertion and T790M.

**EGFR mutations and patient characteristics**

In meta-analysis, we chose 0.01 to 100 as the logarithmic scale (Figure 1). For the comparison between male patients and female patients, ten studies were excluded because patient’s data about gender is patchy. All the other eleven studies [15, 16, 23, 27-30, 33, 34, 36, 37] reported a significant difference between male patients and female patients except Qin B, et al [23] and Wu Y, et al [15]. Heterogeneity analysis revealed that there was no significant between-study heterogeneity in Figure 2. EGFR mutations and their frequency in NSCLC. A. Pie-chart of EGFR mutation frequency by exon in 2039 patients. B. EGFR mutation hotspots from exon 18 to 21 in 1935 patients.
EGFR mutations in mainland Chinese NSCLC patients

Figure 3. Forest plots of relationship between EGFR mutations and the NSCLC patient characteristics. A. Fixed-effects meta-analysis of EGFR mutations with gender (male versus female). B. Fixed-effects meta-analysis of EGFR mutations with smoking history (smoking versus non-smoking). C. Fixed-effects meta-analysis of EGFR mutations with histology type (adenocarcinoma versus non-adenocarcinoma). D. Fixed-effects meta-analysis of EGFR mutations with tumor stage (stage I versus stages II/III/IV).

those 11 studies (chi-squared = 8.51 (d.f. = 0), P = 0.579, I-squared = 0.0%). So, Meta-analysis was performed using fixed-effects model. Overall, male patients with NSCLC had a significantly lower EGFR mutation rate (32.6%, 439/1346) than female patients (53.0%, 548/1033). The pooled OR and 95% CI was 0.40 (0.34-0.48) (P < 0.001) (Figure 3A).

 Associations of EGFR mutations with smoking history were suggested in 10 studies, but 11 studies did not provide the required data. Ten studies were analyzed to examine the relationship between EGFR mutations and smoking history [15, 24-26,
EGFR mutations in mainland Chinese NSCLC patients

31, 32, 36, 37, 39, 40]. For heterogeneity test, chi-squared was 8.79 (d.f. = 9, \(P = 0.457\)) and I-squared was 0.0%. Smokers had a lower EGFR mutation rate (19.2%, 259/1350) than non-smokers (47.9%, 617/1287), with the OR and 95% CI being 0.25 (0.21-0.35) (\(P < 0.001\)) (Figure 3B).

Fifteen studies were eligible to estimate the relationship between EGFR mutations and histology type [14-16, 23, 24, 26, 27, 30, 31, 34, 36-40]. Six studies were excluded because of incomplete information. Between-study heterogeneity could be ignored (chi-squared = 13.77 (d.f. = 14), \(P = 0.467\), I-squared =0.0%). Patients with ADC had a higher EGFR mutation rate (50.2%, 1238/2468) than NADC (17.0%, 226/1333). The pooled OR and 95% CI was 4.84 (4.07-5.75) (\(P < 0.001\)) (Figure 3C).

To further determine the relationship between EGFR mutations and clinic feature of patients, we then compared the frequencies of EGFR mutations in stage I patients and stage II/III/IV. All patients were broadly grouped into stage I or stage II/III/IV groups based on Zhang Y, et al. [28]. Four studies provided information in detail about stage of patients, of which a crude OR was calculated [14, 26, 28, 29]. For heterogeneity test, chi-squared was 2.71 (d.f. = 3, \(P = 0.438\)) and I-squared was 0.0%. There were EGFR mutations in 116/324 (35.8%) of stage I patients, in 245/762 (32.2%) of stage II/III/IV patients. The pooled OR and 95% CI was 1.08 (0.82-1.43) (\(P = 0.580\)) (Figure 3D).

Sensitivity analyses

We performed sensitivity analysis to assess the stability of the results of this meta-analysis by sequentially omitting each study. The leave-one-out sensitivity analysis indicated that no individual study changed the pooled ORs quali-
EGFR mutations in mainland Chinese NSCLC patients

Among those 73 kinds of EGFR mutations in exons 18-21, L858R point mutation was the most major type of EGFR mutations in mainland Chinese patients with NSCLC. The fre-

Discussion

The present report is a meta-analysis with updated data improving our understanding about the EGFR mutation status in NSCLC in mainland China, which may be helpful in targeting patients for better responses to EGFR-TKIs therapy. In this meta-analysis of 5,442 NSCLC cases, 2,039 patients were positive in EGFR mutations. The overall EGFR mutation rate was 37.5%. Thus far, many studies have reported mutational analyses for EGFR gene all over the world. Generally, patients of Asian origin have a higher prevalence compared with Europeans [11-13]. But overall EGFR mutation rate differed widely among Asian regions: 31% in Japan [13], 18.9% in South Korea [41], 27.5% in Taiwan [42], 34.3% in Hong Kong [43]. We found the EGFR mutation rate in unselected cases of NSCLC was 37.5% in mainland China, which was higher than the results from previous Asian population-based studies.

Publication bias

The Begg’s funnel plot and Egger’s test were conducted to assess the publication bias of studies. The shapes of the funnel plots seemed symmetrical in all Meta-analyses, suggesting the absence of publication bias (Figure 5). Then, the Egger’s test was performed to provide statistical evidence of funnel plot symmetry (Table 2). The results indicated no significant evidence for publication bias of the current Meta-analyses. So, bias from publications might not have a significant influence on the results of our meta-analyses.

Figure 5. Results of Begg’s funnel plots. Begg’s funnel plots with pseudo 95% CIs of relationship between EGFR mutations and gender (A), smoking history (B), histology type (C) and tumor stage (D).

tatively, suggesting that our results were stable and reliable (Figure 4).

Publication bias

The Begg’s funnel plot and Egger’s test were conducted to assess the publication bias of studies. The shapes of the funnel plots seemed symmetrical in all Meta-analyses, suggesting the absence of publication bias (Figure 5). Then, the Egger’s test was performed to provide statistical evidence of funnel plot symmetry (Table 2). The results indicated no significant evidence for publication bias of the current Meta-analyses. So, bias from publications might not have a significant influence on the results of our meta-analyses.
EGFR mutations in mainland Chinese NSCLC patients

We also found the EGFR mutations were associated with gender, smoking history, and histology type, but not stage of NSCLC patients (Figure 3). Although the included studies involved different detection methods and tissue samples and the number of cases varied widely, between-study heterogeneity did not have a substantial influence on the results of our meta-analysis (I-squared = 0%). Sensitivity analyses also suggested the stability of this meta-analysis (Figure 4). In concordance with previous reports [10, 14, 17], EGFR mutations are identified at high frequencies in females, never-smokers and adenocarcinoma patients. In mainland China, the EGFR mutations rate was lower in men (OR = 0.40, 95% CI, 0.34-0.48; P < 0.001), smokers (OR = 0.25, 95% CI, 0.21-0.30; P < 0.001), and higher in patients with ADC (OR = 4.84, 95% CI, 4.07-5.75; P < 0.001). This may own to the relationship between NSCLC and smoking, as well as the lifestyle pattern of Chinese women. About 94% mainland Chinese women were non-smokers. Eighty-three percent of Chinese women with lung cancer do not have smoking history [46]. Therefore, both gender and smoking history are confounding factors of affecting EGFR mutations. Moreover, the frequency of EGFR mutations decreased as pack-years increased. EGFR mutations were less common in patients who smoked for more than 15 pack-years or stopped smoking less than 25 years [47]. Thus, TKIs therapy should not be confined to non-smokers with NSCLC, but expanded to former smokers who are less than 15 pack-years or more than 25 years smoke-free. Patients with ADC harbored much higher mutation rate than those with NADC (50.2% versus 17.0%, P < 0.001). The pooled OR and 95% CI was 4.84 (4.07-5.75). So ADC may be used as the prior clinical predictor for EGFR mutations.

In addition, our study failed to find a significant association between the EGFR mutations and tumor stage (OR = 1.08, 95% CI, 0.82-1.43; P = 0.580), which was different from the study of Li.
Z et al. [19]. Li Z et al. reported that EGFR gene mutations were more common in Chinese NSCLC patients advanced stage [19]. Mutation detection methods, specimen types or sampling errors are likely to be the underlying causes of the discordance between our study and Li Z’s. However, our study was consistent with most previous reports [14, 26, 28].

Although Begg’s funnel plot and Egger’s test both indicated the publication bias was not significant (Figure 5, Table 2), it is possible that some relevant publications or unpublished researches or publications in other languages were missed, which might place a bias on our results. There is some evidence that age and tumor differentiation could alter the EGFR mutation rate [32, 36]. However, due to the lack of original data in the publications, we didn’t analyze these factors. Accurate OR should be calculated by age, tumor differentiation and other exposure factors. Due to heterogeneses of EGFR detection methods and technical limitations, it is difficult to unify the depth of sequencing, and the quality of samples. Therefore, the findings of relationship between EGFR mutations and clinicopathological features in this meta-analysis still require further replication with more precise analysis and larger studies to avoid the drawbacks.

Given the heightened interest in targeted therapy against NSCLC, analysis of the EGFR mutation profile from mainland China should be significant. China has the largest pool of NSCLC patients harboring EGFR mutations in the world, representing a fascinating opportunity for the development of TKIs against NSCLC. Therapeutically, mainland Chinese patients carrying the sensitive mutations should respond well to TKIs. Furthermore, most mutations are naturally occurring without exposure to TKIs. Detection of sensitive or resistant EGFR mutations should help to elucidate how different mutations might affect function, dimerization and TKIs sensitivity. Identification of associations between EGFR mutations and clinicopathological features is also conducive to predict the EGFR mutations and identify patients who would respond favorably to EGFR inhibitors.

Disclosure of conflict of interest
None.

Address correspondence to: Dr. Zhou Wang, Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan 250021, Shandong, People’s Republic of China. Tel: 0086-0531-87938911; 0086-1366531-2567; E-mail: wz620226@hotmail.com

References
[9] Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Z et al. [19]. Li Z et al. reported that EGFR gene mutations were more common in Chinese NSCLC patients advanced stage [19]. Mutation detection methods, specimen types or sampling errors are likely to be the underlying causes of the discordance between our study and Li Z’s. However, our study was consistent with most previous reports [14, 26, 28].

Although Begg’s funnel plot and Egger’s test both indicated the publication bias was not significant (Figure 5, Table 2), it is possible that some relevant publications or unpublished researches or publications in other languages were missed, which might place a bias on our results. There is some evidence that age and tumor differentiation could alter the EGFR mutation rate [32, 36]. However, due to the lack of original data in the publications, we didn’t analyze these factors. Accurate OR should be calculated by age, tumor differentiation and other exposure factors. Due to heterogeneses of EGFR detection methods and technical limitations, it is difficult to unify the depth of sequencing, and the quality of samples. Therefore, the findings of relationship between EGFR mutations and clinicopathological features in this meta-analysis still require further replication with more precise analysis and larger studies to avoid the drawbacks.

Given the heightened interest in targeted therapy against NSCLC, analysis of the EGFR mutation profile from mainland China should be significant. China has the largest pool of NSCLC patients harboring EGFR mutations in the world, representing a fascinating opportunity for the development of TKIs against NSCLC. Therapeutically, mainland Chinese patients carrying the sensitive mutations should respond well to TKIs. Furthermore, most mutations are naturally occurring without exposure to TKIs. Detection of sensitive or resistant EGFR mutations should help to elucidate how different mutations might affect function, dimerization and TKIs sensitivity. Identification of associations between EGFR mutations and clinicopathological features is also conducive to predict the EGFR mutations and identify patients who would respond favorably to EGFR inhibitors.

Disclosure of conflict of interest
None.
EGFR mutations in mainland Chinese NSCLC patients


EGFR mutations in mainland Chinese NSCLC patients


